Search Results

With Versant Ventures as a founding investor, Santa Ana Bio emerged from stealth Thursday with $168 million in combined Series A and B funding to support plans to have two programs in the clinic by next year.

Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, emerged from stealth with $168 million in combined Series A and B funding.

Baudax Bio, Inc., a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, announced that U.S. Food and Drug Administration has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors.

Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to advance its portfolio of immunomodulators and oncology therapies.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, announced a $168 million Series B financing.

Design Therapeutics, Inc. announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy, will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting, which is being held in New Orleans from April 23-27, 2023.